Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,616 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COVID-19 in Female and Male Athletes: Symptoms, Clinical Findings, Outcome, and Prolonged Exercise Intolerance-A Prospective, Observational, Multicenter Cohort Study (CoSmo-S).
Widmann M, Gaidai R, Schubert I, Grummt M, Bensen L, Kerling A, Quermann A, Zacher J, Vollrath S, Bizjak DA, Beckendorf C, Egger F, Hasler E, Mellwig KP, Fütterer C, Wimbauer F, Vogel A, Schoenfeld J, Wüstenfeld JC, Kastner T, Barsch F, Friedmann-Bette B, Bloch W, Meyer T, Mayer F, Wolfarth B, Roecker K, Reinsberger C, Haller B, Niess AM; CoSmo-S Consortium. Widmann M, et al. Among authors: vogel a. Sports Med. 2024 Apr;54(4):1033-1049. doi: 10.1007/s40279-023-01976-0. Epub 2024 Jan 11. Sports Med. 2024. PMID: 38206445 Free PMC article.
COVID-19 in German Competitive Sports: Protocol for a Prospective Multicenter Cohort Study (CoSmo-S).
Niess AM, Widmann M, Gaidai R, Gölz C, Schubert I, Castillo K, Sachs JP, Bizjak D, Vollrath S, Wimbauer F, Vogel A, Keller K, Burgstahler C, Quermann A, Kerling A, Schneider G, Zacher J, Diebold K, Grummt M, Beckendorf C, Buitenhuis J, Egger F, Venhorst A, Morath O, Barsch F, Mellwig KP, Oesterschlink J, Wüstenfeld J, Predel HG, Deibert P, Friedmann-Bette B, Mayer F, Hirschmüller A, Halle M, Steinacker JM, Wolfarth B, Meyer T, Böttinger E, Flechtner-Mors M, Bloch W, Haller B, Roecker K, Reinsberger C. Niess AM, et al. Among authors: vogel a. Int J Public Health. 2022 Feb 7;67:1604414. doi: 10.3389/ijph.2022.1604414. eCollection 2022. Int J Public Health. 2022. PMID: 35197815 Free PMC article.
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial.
Heilig CE, Horak P, Kreutzfeldt S, Teleanu V, Mock A, Renner M, Bhatti IA, Hutter B, Hüllein J, Fröhlich M, Uhrig S, Süße H, Heiligenthal L, Ochsenreither S, Illert AL, Vogel A, Desuki A, Heinemann V, Heidegger S, Bitzer M, Scheytt M, Brors B, Hübschmann D, Baretton G, Stenzinger A, Steindorf K, Benner A, Jäger D, Heining C, Glimm H, Fröhling S, Schlenk RF. Heilig CE, et al. Among authors: vogel a. ESMO Open. 2021 Dec;6(6):100310. doi: 10.1016/j.esmoop.2021.100310. Epub 2021 Nov 20. ESMO Open. 2021. PMID: 34808524 Free PMC article.
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.
Vogel A, Sahai V, Hollebecque A, Vaccaro GM, Melisi D, Al Rajabi RM, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Lihou CF, Zhen H, Veronese ML, Abou-Alfa GK. Vogel A, et al. ESMO Open. 2024 Jun 4;9(6):103488. doi: 10.1016/j.esmoop.2024.103488. Online ahead of print. ESMO Open. 2024. PMID: 38838500 Free article.
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, Kitano M, Lee CK, Kim JW, Chen MH, Suksombooncharoen T, Ikeda M, Lee MA, Chen JS, Potemski P, Burris HA 3rd, Ostwal V, Tanasanvimon S, Morizane C, Zaucha RE, McNamara MG, Avallone A, Cundom JE, Breder V, Tan B, Shimizu S, Tougeron D, Evesque L, Petrova M, Zhen DB, Gillmore R, Gupta VG, Dayyani F, Park JO, Buchschacher GL Jr, Rey F, Kim H, Wang J, Morgan C, Rokutanda N, Żotkiewicz M, Vogel A, Valle JW. Oh DY, et al. Among authors: vogel a. Lancet Gastroenterol Hepatol. 2024 May 29:S2468-1253(24)00095-5. doi: 10.1016/S2468-1253(24)00095-5. Online ahead of print. Lancet Gastroenterol Hepatol. 2024. PMID: 38823398
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.
Sangro B, Galle PR, Kelley RK, Charoentum C, De Toni EN, Ostapenko Y, Heo J, Cheng AL, Wilson Woods A, Gupta C, Abraham J, McCoy CL, Patel N, Negro A, Vogel A, Abou-Alfa GK. Sangro B, et al. Among authors: vogel a. J Clin Oncol. 2024 May 28:JCO2301462. doi: 10.1200/JCO.23.01462. Online ahead of print. J Clin Oncol. 2024. PMID: 38805668
1,616 results